21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) Boston, Massachusetts, USA - March 3-6, 2014

S. A. Rizza; Zelalem Temesgen

doi:10.1358/dof.2014.039.04.2145717

21^st Conference on Retroviruses and Opportunistic Infections (CROI 2014) Boston, Massachusetts, USA - March 3-6, 2014

S. A. Rizza, Zelalem Temesgen

Infectious Diseases

Research output: Contribution to journal › Article › peer-review

Abstract

The 21^st Conference on Retroviruses and Opportunistic Infections (CROI) took place in Boston on March 3-6, 2014. A wide variety of important research in the field of HIV medicine and related disciplines was presented, including results from clinical trials of new antiretroviral drugs which are in development, as well as results from studies exploring new strategies of antiretroviral therapy, such as maintenance regimens without the use of nucleoside analogue reverse transcriptase inhibitors. The presentations of new anti-hepatitis C virus (HCV) therapies with high cure rates, short treatment duration and a favorable toxicity profile were the highlight of CROI 2014.

Original language	English (US)
Pages (from-to)	309-316
Number of pages	8
Journal	Drugs of the Future
Volume	39
Issue number	4
DOIs	https://doi.org/10.1358/dof.2014.039.04.2145717
State	Published - Apr 2014

Keywords

Antiretroviral therapy
HCV infection
HIV infection
Nucleoside analogues
Reverse transcriptase inhibitors

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dof.2014.039.04.2145717

Cite this

@article{1bb65bebffd5455dad3799023e8f2f2b,

title = "21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) Boston, Massachusetts, USA - March 3-6, 2014",

abstract = "The 21st Conference on Retroviruses and Opportunistic Infections (CROI) took place in Boston on March 3-6, 2014. A wide variety of important research in the field of HIV medicine and related disciplines was presented, including results from clinical trials of new antiretroviral drugs which are in development, as well as results from studies exploring new strategies of antiretroviral therapy, such as maintenance regimens without the use of nucleoside analogue reverse transcriptase inhibitors. The presentations of new anti-hepatitis C virus (HCV) therapies with high cure rates, short treatment duration and a favorable toxicity profile were the highlight of CROI 2014.",

keywords = "Antiretroviral therapy, HCV infection, HIV infection, Nucleoside analogues, Reverse transcriptase inhibitors",

author = "Rizza, {S. A.} and Zelalem Temesgen",

year = "2014",

month = apr,

doi = "10.1358/dof.2014.039.04.2145717",

language = "English (US)",

volume = "39",

pages = "309--316",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "4",

}

TY - JOUR

T1 - 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) Boston, Massachusetts, USA - March 3-6, 2014

AU - Rizza, S. A.

AU - Temesgen, Zelalem

PY - 2014/4

Y1 - 2014/4

N2 - The 21st Conference on Retroviruses and Opportunistic Infections (CROI) took place in Boston on March 3-6, 2014. A wide variety of important research in the field of HIV medicine and related disciplines was presented, including results from clinical trials of new antiretroviral drugs which are in development, as well as results from studies exploring new strategies of antiretroviral therapy, such as maintenance regimens without the use of nucleoside analogue reverse transcriptase inhibitors. The presentations of new anti-hepatitis C virus (HCV) therapies with high cure rates, short treatment duration and a favorable toxicity profile were the highlight of CROI 2014.

AB - The 21st Conference on Retroviruses and Opportunistic Infections (CROI) took place in Boston on March 3-6, 2014. A wide variety of important research in the field of HIV medicine and related disciplines was presented, including results from clinical trials of new antiretroviral drugs which are in development, as well as results from studies exploring new strategies of antiretroviral therapy, such as maintenance regimens without the use of nucleoside analogue reverse transcriptase inhibitors. The presentations of new anti-hepatitis C virus (HCV) therapies with high cure rates, short treatment duration and a favorable toxicity profile were the highlight of CROI 2014.

KW - Antiretroviral therapy

KW - HCV infection

KW - HIV infection

KW - Nucleoside analogues

KW - Reverse transcriptase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84930539626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930539626&partnerID=8YFLogxK

U2 - 10.1358/dof.2014.039.04.2145717

DO - 10.1358/dof.2014.039.04.2145717

M3 - Article

SN - 0377-8282

VL - 39

SP - 309

EP - 316

JO - Drugs of the Future

JF - Drugs of the Future

IS - 4

ER -